Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | -0.35 | 0.73 | -148.19 |
| EPS, GAAP | -0.35 | 0.73 | 0.73 |
| Consensus Estimate | -0.05 | 0.77 | -106.49 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | -0.50 | 0.56 | -189.16 |
| EPS, GAAP | -0.50 | 0.14 | -456.55 |
| Consensus Estimate | -0.18 | 0.10 | -280.00 |
| VRTX | Industry Average | |
| P/E (TTM) | 0.00 | NA |
| P/E (Forward) | 0.00 | NA |
| PEG Ratio | 0.00 | 2.20 |
| Price/Sales | 7.39 | 18.91 |
| Beta | 0.87 | 0.70 |
| 8:42 AM | 4/5/2013 | Vertex Signs Deal With Bristol-Myers for Hepatitis C Treatment Studies |
| 3/22/2013 | Low-Quality Stocks Have Zoomed. Time to Shift Gears? (WSJ.com) |
| 1/15/2013 | Top Analyst Upgrades and Downgrades (AFL, AXP, AINV, ARMH, BIIB, CELG, CS, DELL, GMCR, INFY, LOGI, LYG, MLNX, NKTR, PDLI, PCYC, REGN, RBS, UAL, LCC, VRTX, VPHM, WFT) (24/7 Wall St) |
| 12/5/2012 | FDA Drug Approvals Increase (WSJ.com) |
